Cellectis SA/ FR0010425595 /
| 8/12/2022 5:35:03 PM | Chg. -0.010 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | High | Low |
|---|---|---|---|---|---|---|
| 3.614EUR | -0.28% | 356,178 Turnover: 1.26 mill. |
3.600Bid Size: 4,426 | 3.630Ask Size: 542 | 3.690 | 3.420 |
GlobeNewswire
3/23
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-De...
GlobeNewswire
3/16
Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Mult...
GlobeNewswire
3/15
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Ed...
GlobeNewswire
3/10
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-...
GlobeNewswire
3/3
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
GlobeNewswire
2/24
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
GlobeNewswire
2/24
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Up...
GlobeNewswire
2/23
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Busin...
GlobeNewswire
2/18
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Fact...
GlobeNewswire
1/10
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their ...
GlobeNewswire
1/10
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
GlobeNewswire
1/4
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
GlobeNewswire
12/13/2021
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 ...
GlobeNewswire
12/13/2021
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma ...
GlobeNewswire
12/11/2021
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute ...
GlobeNewswire
12/9/2021
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating ...
GlobeNewswire
11/18/2021
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboratio...
GlobeNewswire
11/12/2021
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate T...
GlobeNewswire
11/9/2021
Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
GlobeNewswire
11/4/2021
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Mo...
GlobeNewswire
11/4/2021
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update